Peyronie’s disease is sometimes called “curved privates disease” or simply “curvature” because the scar tissue (or plaque) causes the privates to bend when aroused. However, many curved privates are ...

Peyronie’s disease is epitomized by fibroblast proliferation in the tunica albuginea (a fascial structure in the penis), giving rise to a thick fibrous plaque that may result in pain, pathological ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Men with Peyronie’s disease demonstrated an increased ...

Peyronie’s Disease is a common, sexually debilitating fibrosing disorder of the penis that results in plaque formation and subsequent penile deformity. Once considered a rare condition, it can be ...

Men with a rare disease that causes curvature of the penis are at higher risk of developing several cancers, a large-scale study has found. The research, which looked at over 1.5 million men and was ...

The study population consisted of patients with documented Peyronie's disease and penile curvature of at least 1-y duration who underwent either surgical correction of their penile curvature or ...

Xiaflex provides an alternative to surgery to treat Peyronie’s disease. It is the first medication approved by the agency for treating this erectile problem. Urologists for the first time have an ...

Urologist Dr. John Smith tells us why Peyronie's disease happens, when to be concerned, and how to choose the best treatment option. This episode is part of our Men's Health Essentials Series: ...

The US Food and Drug Administration (FDA) has approved collagenase clostridium histolyticum (Xiaflex, Auxilium Pharmaceuticals) for the treatment of men with Peyronie's disease. "Xiaflex is the first ...

The Food and Drug Administration (FDA) has approved Xiaflex as the first non-surgical treatment for Peyronie’s disease (PD), a condition that causes penis curvature that can make sexual intercourse ...

MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...